• Save €3.03

ACTIFED * 12CPR 2,5MG + 60MG

  • 018723080

Indicated in case of nasal congestion.

Indicated in case of cold.

Deductible over-the-counter drug.

It can induce sleepiness.

info_outline View product sheet
Final Price €9.40
Regular Price €12.43
Save €3.03
check_circle Available (14 Items)

redeem loyalty points

By buying this product you can collect up to 9 loyalty points that can be converted into a voucher. More info

  Convenient and safe payments

Even with a credit card

  Shipping in 48h-72h all over the world

FREE in Italy over € 39.90

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service

Other products Others products at unbeatable price


Discover all products

ACTIFED * 12CPR 2,5MG + 60MG

Therapeutic indications

Decongestant of the nasal mucosa, especially in case of colds.

Dosage and method of use

Dosage.ACTIFED syrup: A measuring cup is attached to the package with level marks corresponding to the capacities of 5 and 10 ml.Adults and children over 12 years old: a dose of 10 ml of syrup 2 - 3 times a day.ACTIFED tablets. Adults and children over 12 years:one tablet 2 - 3 times a day.Do not exceed the recommended dose.Method of administration:Oral use


- hypersensitivity to the active substances, to other antihistamines or to any of the excipients listed in section 6.1; - children under the age of 12; - Pregnancy and breastfeeding; - in patients being treated with monoamine oxidase inhibitors (MAOIs) or in the two weeks following such treatment, and in the treatment of lower respiratory tract diseases, including bronchial asthma. In such cases, concomitant use of ACTIFED may cause an increase in blood pressure or hypertensive crisis; - glaucoma, prostatic hypertrophy, bladder neck obstruction, pyloric and duodenal stenosis or other tracts of the gastrointestinal and urogenital tract (due to its anticholinergic effects); - cardiovascular diseases, arterial hypertension, hyperthyroidism, epilepsy and diabetes.

Side effects

Adverse reactions reported with a frequency ≥1%, identified in randomized placebo-controlled trials, with formulations containing pseudofedrine as a single active substance are presented below: dry mouth, nausea, dizziness, insomnia and nervousness. There are no placebo-controlled clinical trials with sufficient adverse reaction data for the combination of the active substances pseuoephedrine and triprolidine. Adverse reactions identified during post-marketing experience with pseudoephedrine, triprolidine or the combination are presented in Table 1 according to frequency categories using the following convention: very common (≥ 1/10); common (≥ 1/100 e

Psychiatric disorders
Very rare Anxiety, euphoric mood, hallucination, restlessness, visual hallucination.
Nervous system disorders
Very Rare Headache, paraesthesia, psychomotor hyperactivity (in the pediatric population), somnolence, tremor.
Not known Cerebrovascular accident *, posterior reversible encephalopathy (PRES), reversible cerebral vasoconstriction syndrome (RCVS) (see section 4.4)
Cardiac pathologies
Very Rare Arrhythmia, extrasystoles, palpitations, tachycardia
Not known Myocardial infarction / Myocardial ischaemia *
General disorders and administration site conditions
Very Rare Asthenia.
Disorders of the immune system
Very rare Hypersensitivity
Respiratory, thoracic and mediastinal disorders
Very rare Epistaxis
Gastro-intestinal disorders
Very rare Vomiting, abdominal discomfort.
Not known Ischemic colitis (see section 4.4) *
Skin and subcutaneous tissue disorders
Very rare Itching, rash, hives, angioedema. Acute generalized exanthematous pustulosis (AGEP) (see section 4.4), angioedema.
Renal and urinary disorders
Very rare Dysuria, urinary retention.
Diagnostic tests
Very rare Blood pressure increased.
Eye disorders
Not known Ischemic optic neuropathy

* adverse reactions collected during post-marketing experience with pseudoephedrine ACTIFED can also cause dizziness, photosensitivity reaction, diarrhea, hyperviscosity of bronchial secretions, very rarely blood disorders and especially in the elderly, hypotension.Reporting of suspected adverse reactions.Reporting of suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit / risk ratio of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioniavverse.

Special warnings

If symptoms persist or worsen or if new symptoms appear, patients should discontinue use of the medicine and consult a physician. If symptoms do not improve within 7 days or if there is a high fever or other side effects, patients should be advised to stop treatment and consult their physician. Before taking triprolidine, patients with the following respiratory conditions such as emphysema, chronic bronchitis or acute or chronic bronchial asthma should be advised to consult a physician. Triprolidine can cause drowsiness and can increase the sedative effects of substances that depress the central nervous system such as alcohol, sedatives, tranquilizers. Patients should be advised that alcoholic beverages should be avoided during treatment with ACTIFED and that they should consult their physician before taking ACTIFED concomitantly with central nervous system depressant medications. At common therapeutic doses, antihistamines exhibit highly variable secondary reactions from subject to subject and from compound to compound. For the posology in the elderly it is necessary to consider their greater sensitivity to antihistamines and to pseudoephedrine. Although pseudoephedrine did not produce important effects on blood pressure in normotensive subjects, ACTIFED should not be taken by patients on antihypertensive, tricyclic antidepressant, sympathomimetic agents such as decongestants, anorexics, amphetamine-like agents. Rare cases of posterior reversible encephalopathy have been reported with sympathomimetic drugs, including pseudoephedrine (posterior reversible encephalopathy, PRES) / reversible cerebral vasoconstriction syndrome (reversible cerebral vasoconstriction syndrome, RCVS). Symptoms reported include sudden onset of severe headache, nausea, vomiting and visual disturbances. If signs or symptoms of PRES / RCVS develop, pseudoephedrine treatment should be discontinued and a physician should be consulted immediately. Ischemic colitis: A few cases of ischemic colitis have been reported with medicinal products containing pseudoephedrine. If sudden abdominal pain, rectal tenesmus, rectal bleeding or other symptoms of ischemic colitis develop (see section 4.8), the use of pseudoephedrine should be discontinued and a physician should be consulted. Ischemic optic neuropathy Cases of ischemic optic neuropathy have been reported with pseudoephedrine. Pseudoephedrine should be discontinued if sudden loss of vision or decreased visual acuity occurs, for example in the case of scotoma. Skin safety: Serious skin reactions such as acute and generalized exanthematous pustulosis (AGEP) can occur with products containing pseudoephedrine. This acute pustular rash can occur within the first 2 days of treatment, with fever and numerous, small, mostly non-follicular pustules resulting from a widespread edematous erythema and located mainly on the skin folds, trunk and upper limbs. Patients must be carefully monitored. If signs and symptoms such as pyrexia, erythema, or numerous small pustules are observed, administration of ACTIFED should be discontinued and appropriate measures taken if necessary (see section 4.8). ACTIFED should not be used by patients with severe liver disease or with reduced kidney function unless your doctor deems it necessary.Important information about some of the ingredients:ACTIFED syrupcontains: - Sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. This medicine contains 7 g of sucrose per dose. To be taken into consideration in people with diabetes mellitus; - Methyl para-hydroxybenzoate. It can cause allergic reactions (even delayed); - Sunset yellow (E110). It can cause allergic reactions.ACTIFED tabletscontains lactose: - Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.

Pregnancy and breastfeeding

ACTIFED is contraindicated during pregnancy and breastfeeding.

Expiry and retention

ACTIFED syrup: Keep away from light.ACTIFED tablets:Store at a temperature not exceeding 25 ° C, in a dry place.

Interactions with other drugs

Acute hypertensive crises have been reported in the medical literature during concomitant use of monoamine oxidase inhibitors (MAOIs) and sympathomimetic amines. Pseudoephedrine exerts a vasoconstrictive action by stimulating adrenergic receptors and releasing noradrenaline from neuronal sites. Monoamine oxidase inhibitors (MAOIs) may potentiate the pressure effect of pseudoephedrine by preventing the metabolism of sympathomimetic amines and increasing the releasable amount of norepinephrine in the adrenergic nervous tissue. The effects of antihistamines are made more evident by alcohol, hypnotics, sedatives, tranquilizers, and other substances with anticholinergic action or depressant effect on the central nervous system, which therefore should not be taken during therapy. Antihistamines can reduce the duration of action of oral anticoagulants. The use of antihistamines can mask the early signs of ototoxicity of certain antibiotics. Furazolidone causes a progressive inhibition of monoamine oxidase, so it should not be taken at the same time as ACTIFED. The effect of antihypertensives that interfere with sympathetic activity (e.g. methyldopa, alpha and beta blockers, debrisoquine, guanethidine, betanidine and bretylium) can be partially canceled by ACTIFED, which therefore, even in this case, does not go simultaneously hired.


In case of overdose, marked depressive (due to triprolidine) or stimulating (due to pseudoephedrine) effects on the CNS are generally observed Effects of triprolidine: drowsiness, lethargy, respiratory depression, hypertension, hyperthermia, anticholinergic syndrome (mydriasis, redness, fever, mouth dryness, urinary retention, reduced borborygmas) tachycardia, hypotension, nausea, vomiting, agitation, confusional state, hallucinations, psychosis, convulsions, arrhythmias. Patients suffering from prolonged agitation, coma, or seizures may rarely experience rhabdomyolysis and renal failure Effects of pseudoephedrine: overdose may cause nausea, vomiting, sympathomimetic symptoms including CNS stimulation, insomnia, mydriasis, irritability, seizures, anxiety, agitation, hallucinations, palpitations, tachycardia, hypertension, reflex bradycardia. Other effects may include arrhythmias, hypertensive crisis, intracerebral haemorrhage, myocardial infarction, psychosis, rhabdomyolysis, hypokalemia, intestinal infarction. In children the dominant action is the exciting one with accentuated tremors, insomnia, hyperactivity and convulsions, drowsiness has also been reported. Keep out of reach of children. In case of overdose, get medical help or contact a poison control center right away.

Active principles

One tablet contains: Active ingredients: triprolidine hydrochloride 2.5 mg; pseudoephedrine hydrochloride 60.0 mg. Excipients with known effects: lactose.ACTIFED syrup100 of syrup contain: - active ingredients: triprolidine hydrochloride 0.025 g; pseudoephedrine hydrochloride 0.600 g; - excipients with known effects: sucrose, methyl para hydroxybenzoate, sunset yellow (E110). For the full list of excipients, see section 6.1.


ACTIFED tablets. Each tablet contains: lactose; cornstarch; povidone; magnesium stearate. ACTIFED syrup. 100 ml of syrup contain: glycerol; sucrose; methyl para-hydroxybenzoate; sodium benzoate; quinoline yellow (E104); sunset yellow (E110); purified water.

14 Items

Data sheet

2.5 mg + 60 mg 12 tablets
Product Type
ATC code
ATC description
Pseudoephedrine, associations
Therapeutic Group
Active principle
pseudoephedrine + triprolidine
Pharmaceutical form
Type of Administration
cpr / cps / pills / confetti in blister packs
12 tablet
Quantity of the Active Ingredient
60MG (pseudoephedrine hydrochloride) + 2.5MG (triprolidine hydrochloride)
Recipe required
OTC - self-medication medicine